Precision medicine for severe asthma - Biological targeted therapy

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Severe asthma is a complex, heterogeneous chronic airway inflammatory disease.
• Current treatments are shifting towards personalized medicine.
• Biomarkers and targeted therapies are crucial for tailored approaches.

Purpose of the Study:

• To provide a comprehensive review of biomarkers and biological agents for severe asthma.
• To highlight the transformative impact of biological agents on severe asthma management.
• To emphasize the need for further research into pathogenesis and novel treatments.

Main Methods:

• Review of current literature on severe asthma biomarkers.
• Analysis of approved biological agents (monoclonal antibodies) targeting specific inflammatory pathways.
• Discussion of clinical efficacy and patient-reported outcomes.

Main Results:

• Approved biological agents (anti-IgE, anti-IL-4, anti-IL-5, anti-TSLP) show significant efficacy.
• These agents reduce asthma exacerbations, improve lung function, and decrease oral corticosteroid use.
• Patient quality of life is notably enhanced.

Conclusions:

• Biomarkers and biological agents are revolutionizing severe asthma treatment.
• Personalized therapeutic strategies are becoming standard.
• Continued research into pathogenesis and new treatments is essential for further progress.